Protocolo de tratamiento de la cardiotoxicidad en la cardio-oncología
- Zatarain Nicolás, E. 1
- Herrera Flores, C. 1
- Bermejo, J. 1
- Fernández Avilés, F. 1
- 1 Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, Madrid, España Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, España Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España CIBERCV, Instituto de Salud Carlos III, Madrid, España
ISSN: 0304-5412
Year of publication: 2021
Issue Title: Enfermedades cardiovasculares (VII)
Series: 13
Issue: 41
Pages: 2411-2415
Type: Article
More publications in: Medicine: Programa de Formación Médica Continuada Acreditado
Abstract
Primary and secondary prevention of cardiovascular disease is important in all cancer patients, but especially critical in those exposed to cardiotoxic therapies. Consequently, a comprehensive evaluation of the baseline risk of cardiotoxicity is essential before the patient starts the treatment and a correct follow-up until its completion. Cancer therapeutics-related cardiac dysfunction (CTRCD) merits further consideration, and its management is detailed below. The optimal approach to surveillance cancer survivors is controversial, although some basic recommendations have been made in this regard.
Bibliographic References
- Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F. Cardiovascular toxicity related to cancer treatment: A pragmatic approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc. 2020;9:e018403.
- Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020;31:171-90.
- López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García Sanz R, Mazón Ramos P. Cardio-oncohematología en la práctica clínica. Documento de consenso y recomendaciones. Rev Esp Cardiol. 2017;70:474-86.
- Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22:1945-60.
- Martín García A, Mitroi C, Mazón Ramos P, García Sanz R, Virizuela JA, Arenas M. Estratificación, monitorización y control del riesgo cardiovascular en pacientes con cáncer. Documento de consenso de SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC y AECC. 2021 May;74(5):438-48.
- Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S,. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1966-83.